News Release

Your Contact
Heather Connor +1 978-294-1660

April 14, 2016

Merck KGaA, Darmstadt, Germany, to Present Data On Comparative Effectiveness of Rebif® versus Oral Therapy at AAN Annual Meeting

- **Real-world data of relapse rates in patients with Multiple Sclerosis (MS) newly initiating self-treatment with interferon beta-1a (Rebif®) to be presented**

Darmstadt, Germany, April 14, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that clinical and real-world data about interferon beta-1a (Rebif®), will be presented at the American Academy of Neurology's (AAN) 68th Annual Meeting, taking place April 15-21, 2016, in Vancouver, British Columbia, Canada.

A real-world assessment of relapse rates in patients with MS newly initiating self-injectable treatment with interferon beta-1a versus an oral disease-modifying therapy, as well as the clinical effect of interferon beta-1a on 'no evident disease activity' (NEDA) and MRI outcomes, will be revealed in data presented by Merck KGaA, Darmstadt, Germany.

"Patients with MS have more choices than ever before, but, given the potential devastation of this disease, consistent validation and balance of comparative effectiveness is paramount to selecting the most appropriate treatment," said Rick Munschauer, Vice President, Medical Affairs, Neurology and Immunology, EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S and Canada. "We are committed to enhancing care for people living with MS. That commitment includes continuing to deepen our understanding of the clinical and real-world impact of Rebif to inform the most optimal choice of therapy

Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt · Germany
Hotline +49 6151 72-5000
emdgroup.com

Head Media Relations -62445
Spokesperson: -9591 / -7144 / -6328
Fax +49 6151 72 3138
media.relations@emdgroup.com

News Release

for patients. With a well-established safety profile supported by more than 20 years of combined clinical trial and patient experience and efficacy across three key disease measures – including reducing relapse rates and delaying disability progression – Rebif is an important treatment option for relapsing MS."

The following abstracts have been accepted for presentation at the 68th AAN Annual meeting:

Title	Lead Author	Abstract/ Poster #	Presentation date/time	Session
Predictive Value of 6-Month T2 and Enhancing Lesions Among Patients with RRMS Receiving Interferon β-1a Subcutaneously Thrice Weekly or Placebo: Post Hoc Analyses of PRISMS Data	D. Li	P1.401	April 16, 2016 5:30 p.m.	Poster Session P1: 8:30 a.m. to 7:00 p.m.
Age-, Sex-, and Geographic Region-Specific Comorbidity in Patients with Multiple Sclerosis	NC. Edwards	P2.190	April 17, 2016 4:00 p.m.	Poster Session P2: 8:30 a.m. to 5:30 p.m.
Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study	G. Comi	P2.114	April 17, 2016 4:00 p.m.	Poster Session P2: 8:30 a.m. to 5:30 p.m.
Role of Family Planning in Women of Child-Bearing Age with Multiple Sclerosis (MS) in Switzerland: Results of the Women with MS (WWMS) Patient Survey	S. Muehl	P2.105	April 17, 2016 4:00 p.m.	Poster Session P2: 8:30 a.m. to 5:30 p.m.

News Release

Adherence to Subcutaneous IFN-β1a - Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart®	P. Rieckmann	P3.098	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Association of Timing of Disease-Modifying Drug Treatment Initiation on Multiple Sclerosis Relapse Rates in Newly Diagnosed Patients	AL. Phillips	P3.118	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study	G. Giovannoni	P3.028	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Effect of Early Versus Delayed Subcutaneous Interferon (scIFN) β-1a to Achieve No Evidence of Disease Activity (NEDA) in Patients with Clinically Isolated Syndrome (CIS): a Post-Hoc Analysis of REFLEXION	P. Coyle	P3.111	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Efficacy of Cladribine Tablets* as Add-On to IFN-Beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study	X. Montalban	P3.029	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Efficacy of Cladribine Tablets* in ORACLE Study Patients who Retrospectively Met 2010 McDonald Multiple Sclerosis (MS) Criteria at Baseline	MS. Freedman	P3.035	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.

News Release

Interferon β-1a SC tiw Reduces Mild to Moderate and Moderate to Severe Relapses and Disease Activity over 1 Year in Patients with Relapsing MS: Post Hoc Analyses of PRISMS Data	A. Boster	P3.036	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Natural and Inducible Regulatory T Cell Subsets in a Large Cohort of Relapsing Remitting Multiple Sclerosis Patients Treated with Interferon-Beta and Followed for 24 Months	F. Serana	P3.077	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Safety and Tolerability of Cladribine Tablets* in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study	S. Cook	P3.095	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets* in the CLARITY Study: a Post-Hoc Subgroup Analysis	S. Cook	P3.058	April 18, 2016 5:30 p.m.	Poster Session P3: 8:30 a.m. to 7:00 p.m.
MRI Frequency and No Evidence of Disease Activity Status Among Patients with RRMS Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of EVIDENCE	AT. Reder	P6.190	April 21, 2016 4:00 p.m.	Poster Session P6: 8:30 a.m. to 5:30 p.m.

News Release

Predictive Value of Early MRI Measures for Long-Term Disease Activity in Patients with Relapsing–Remitting Multiple Sclerosis Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of the EVIDENCE Study	PK. Coyle	P6.189	April 21, 2016 4:00 p.m.	Poster Session P6: 8:30 a.m. to 5:30 p.m.
Real-World Assessment of Relapse Rates in Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon β-1a vs Oral Disease-Modifying Drugs	CM. Kozma	P6.178	April 21, 2016 4:00 p.m.	Poster Session P6: 8:30 a.m. to 5:30 p.m.

**Cladribine tablets is an investigational product and not approved for use in any indication in the United States. RebiSmart®, an electronic device for self-injection of Rebif®, is also not approved in the United States.*

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.